<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02100904</url>
  </required_header>
  <id_info>
    <org_study_id>14-13325</org_study_id>
    <nct_id>NCT02100904</nct_id>
  </id_info>
  <brief_title>Uterine Leiomyoma Treatment With Radiofrequency Ablation (ULTRA) Registry</brief_title>
  <acronym>ULTRA Registry</acronym>
  <official_title>Uterine Leiomyoma Treatment With Radiofrequency Ablation (ULTRA) Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <brief_summary>
    <textblock>
      The ULTRA Registry is a nationwide observational arm of the ULTRA trial. Data from the ULTRA
      Registry will be used to evaluate the long-term safety and efficacy of laparoscopic RF
      ablation (Acessa).

      The ULTRA Registry will recruit women age 21 or older who plan to undergo or have undergone
      laparoscopic RF ablation (Acessa) or myomectomy within the United States. Participants will
      be recruited through study materials distributed at clinical offices across the country where
      gynecologists are performing laparoscopic RF ablation (Acessa). Study participants will
      consent to participate in a 3 year prospective study conducted by UCSF but the fibroid
      procedure will be performed by the study participants' own gynecologist. We will evaluate
      changes in fibroid-related symptoms from pre-treatment values to 6, 12, 18, 24, 30, and 36
      months after RFA (Acessa). We will determine long-term efficacy of RFA (Acessa) by evaluating
      the rate of re-treatment for symptomatic fibroids after the RFA (Acessa) procedure versus
      myomectomy. Participants will be asked for permission to review their medical records to
      assess surgical and pregnancy outcomes.

      UC San Francisco will have oversight of all scientific and administrative aspects of the
      study. All study data will be stored securely in a HIPAA compliant, secure database monitored
      by the UC San Francisco Coordinating Center.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in fibroid-related symptoms after the RFA or myomectomy procedure.</measure>
    <time_frame>Baseline to 3 years</time_frame>
    <description>We will use standard questionnaires for women with fibroids to assess changes in fibroid symptoms including menstrual pattern and flow and overall quality of life.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of re-intervention for recurrent fibroid symptoms following the RFA or myomectomy procedure.</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative complications</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
    <description>Operative complications are rare but may include excessive blood loss, uterine or pelvic infection, injury to organs adjacent to uterus such as bowel or bladder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy rate after the RFA or myomectomy procedure.</measure>
    <time_frame>Baseline to 3 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Uterine Fibroids</condition>
  <arm_group>
    <arm_group_label>Women undergoing radiofrequency ablation.</arm_group_label>
    <description>Most women (75%) in the trial will be in the group who receive treatment with radiofrequency ablation (Acessa).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Women undergoing myomectomy</arm_group_label>
    <description>About 25% of women in the trial will be in the group who receive treatment with myomectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiofrequency ablation of fibroids</intervention_name>
    <arm_group_label>Women undergoing radiofrequency ablation.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Myomectomy of fibroids</intervention_name>
    <arm_group_label>Women undergoing myomectomy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women with uterine fibroids who are planning to undergo or have undergone radiofrequency
        ablation (Acessa) or myomectomy treatment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Planning to undergo or have undergone* RF ablation (Acessa) or myomectomy
             (laparoscopic or abdominal) for treatment of uterine fibroids.

          -  Able to give informed consent

          -  Speak English or Spanish

               -  Women enrolled at contracted clinical sites must enroll prior to their RF
                  ablation treatment

        Exclusion Criteria:

          -  &lt;21 years of age

          -  Plan to undergo hysteroscopic myomectomy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vanessa Jacoby, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vanessa Monzon</last_name>
    <phone>510-999-4326</phone>
    <email>fibroids@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ruth Gebrezghi</last_name>
    <phone>510-999-4326</phone>
    <email>fibroids@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Deyna Arrellano</last_name>
      <phone>858-822-2916</phone>
    </contact>
    <investigator>
      <last_name>Shira Varon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dedicated to Women</name>
      <address>
        <city>Dover</city>
        <state>Delaware</state>
        <zip>19904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Kline</last_name>
      <phone>302-674-0223</phone>
    </contact>
    <investigator>
      <last_name>Robert Hartmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fibroid and Pelvic Wellness Center of Georgia</name>
      <address>
        <city>Alpharetta</city>
        <state>Georgia</state>
        <zip>30005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Compres</last_name>
      <phone>770-475-4499</phone>
    </contact>
    <contact_backup>
      <last_name>Jessica Sanders</last_name>
      <phone>(770) 475-4499</phone>
    </contact_backup>
    <investigator>
      <last_name>Soyini Hawkins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gynecology Institute of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Halfmann</last_name>
      <phone>312-929-9191</phone>
    </contact>
    <investigator>
      <last_name>Nicole Williams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women's Healthcare Associates of IL, SC</name>
      <address>
        <city>Homewood</city>
        <state>Illinois</state>
        <zip>60430</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Devra Gills</last_name>
    </contact>
    <investigator>
      <last_name>Biren Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bonnie Thiele</last_name>
    </contact>
    <investigator>
      <last_name>Craig Sobolewski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giselle Huet</last_name>
    </contact>
    <contact_backup>
      <phone>214-648-9464</phone>
    </contact_backup>
    <investigator>
      <last_name>Kimberly A Kho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MacArthur Medical Center</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75062</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jai Fields</last_name>
    </contact>
    <investigator>
      <last_name>Brian Enggano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Acacia OBGYN</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Guillen</last_name>
      <phone>210-852-6788</phone>
    </contact>
    <investigator>
      <last_name>Henry Garza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.ucsf.edu/fibroids</url>
    <description>Fibroid Trials at UCSF</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>March 27, 2014</study_first_submitted>
  <study_first_submitted_qc>March 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2014</study_first_posted>
  <last_update_submitted>December 19, 2019</last_update_submitted>
  <last_update_submitted_qc>December 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fibroids</keyword>
  <keyword>Radiofrequency ablation</keyword>
  <keyword>Myomectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

